Department of Internal Medicine I, Division of Haematology & Haemostaseology, Medical University of Vienna, Vienna, Austria (P. Valent, W.R. Sperr, A.W. Hauswirth), Department of Internal Medicine, Division of Allergy and Immunology, University of Michigan, Ann Arbor, MI, USA (C. Akin), Servicio de Hematologia, Unidad de Mastocitosis, Hospital Ramón y Cajal, Madrid, Spain (L. Escribano), Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Austria (M. Födinger), Clinic and Polyclinic of Dermatology & Venerology, University of Cologne, Germany (K. Hartmann), Department of Dermatology and Allergy Biederstein, Technical University of Munich, Germany (K. Brockow), Division of Rheumatology, Immunology & Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA (M. Castells), Department of Haematology, University Medical Centre Groningen, Groningen, the Netherlands (H.C. Kluin-Nelemans), Department of Endocrinology & Metabolic Diseases, Leiden University Medical Centre, Leiden, the Netherlands (N.A.T. Hamdy), Université Paris V, Hôpital Necker-Enfants Malades, Service des Maladies Infectieuses (O. Lortholary), Haematology Branch, National Heart Lung and Blood Institute, NIH Bethesda, MD, USA (J. Robyn), Department of Allergology, University Hospital Groningen, Groningen, the Netherlands (J. van Doormaal), Institute of Pathology, University of Tübingen, Germany (K. Sotlar), LBPA CNRS UMR 8113, Ecole Normale Supérieure de Cachan, Cachan, France (M. Arock), Department of Adult Haematology, and CNRS UMR 8147, Univesité René Descarte, Assistance Publique Hôpitaux de Paris, Hôpital Necker, Paris, France (O. Hermine), Department of Haematology, Medical University of Gdansk, Poland (A. Hellmann), Facolta Medicina e Chirurgia, Cattedra di Immunologia Clinica e Allergologia Universitá degli studi di Napoli Federico II, Naples, Italy (M. Triggiani), Department of Allergology, Medical University of Gdansk, Poland (M. Niedoszytko), Department of Internal Medicine, Division of Rheumatology, Allergy & Immunology, Virginia Commonwealth University, Richmond, VA, USA (L.B. Schwartz), Servicio Central de Citometria, Centro de Investigacion del Cancer and Department of Medicine, University of Salamanca, Spain (A. Orfao), Institute of Pathology, University of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany (H.-P. Horny), Laboratory of Allergic Diseases, NIAID, NIH, Bethesda, MD, USA (D.D. Metcalfe).
Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria
Article first published online: 26 MAY 2007
European Journal of Clinical Investigation
Volume 37, Issue 6, pages 435–453, June 2007
How to Cite
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin-Nelemans, H. C., Hamdy, N. A. T., Lortholary, O., Robyn, J., Van Doormaal, J., Sotlar, K., Hauswirth, A. W., Arock, M., Hermine, O., Hellmann, A., Triggiani, M., Niedoszytko, M., Schwartz, L. B., Orfao, A., Horny, H.-P. and Metcalfe, D. D. (2007), Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria. European Journal of Clinical Investigation, 37: 435–453. doi: 10.1111/j.1365-2362.2007.01807.x
This article is dedicated to the achievements of Professor Reza M. Parwaresch who passed away shortly before the start of the Working Conference.
- Issue published online: 26 MAY 2007
- Article first published online: 26 MAY 2007
- Received 1 December 2006; Accepted 13 February 2007
- patient selection;
- targeted drugs
Although a classification for mastocytosis and diagnostic criteria are available, there remains a need to define standards for the application of diagnostic tests, clinical evaluations, and treatment responses. To address these demands, leading experts discussed current issues and standards in mastocytosis in a Working Conference. The present article provides the resulting outcome with consensus statements, which focus on the appropriate application of clinical and laboratory tests, patient selection for interventional therapy, and the selection of appropriate drugs. In addition, treatment response criteria for the various clinical conditions, disease-specific symptoms, and specific pathologies are provided. Resulting recommendations and algorithms should greatly facilitate the management of patients with mastocytosis in clinical practice, selection of patients for therapies, and the conduct of clinical trials.